Gilead Sciences, Inc. to Post FY2020 Earnings of $6.51 Per Share, Oppenheimer Forecasts (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities research analysts at Oppenheimer decreased their FY2020 earnings per share (EPS) estimates for shares of Gilead Sciences in a note issued to investors on Monday, September 14th. Oppenheimer analyst H. Singh now anticipates that the biopharmaceutical company will post earnings per share of $6.51 for the year, down from their previous forecast of $6.56. Oppenheimer has a “Outperform” rating and a $105.00 price target on the stock. Oppenheimer also issued estimates for Gilead Sciences’ Q4 2020 earnings at $2.05 EPS, FY2021 earnings at $8.58 EPS and FY2022 earnings at $9.00 EPS.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.46). Gilead Sciences had a positive return on equity of 33.59% and a negative net margin of 1.16%. The business had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.24 billion.

A number of other brokerages have also issued reports on GILD. Citigroup raised their price target on Gilead Sciences from $78.00 to $80.00 in a research note on Monday, August 3rd. ValuEngine upgraded Gilead Sciences from a “strong sell” rating to a “sell” rating in a research note on Monday, August 3rd. Robert W. Baird reaffirmed a “hold” rating and set a $76.00 price target on shares of Gilead Sciences in a research report on Monday, June 29th. Credit Suisse Group lowered their price target on Gilead Sciences from $75.00 to $73.00 and set a “neutral” rating for the company in a research report on Friday, July 31st. Finally, BidaskClub cut Gilead Sciences from a “sell” rating to a “strong sell” rating in a research report on Friday, July 24th. Four research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $78.78.

NASDAQ:GILD opened at $66.20 on Wednesday. The firm has a market capitalization of $83.00 billion, a price-to-earnings ratio of -275.82, a PEG ratio of 0.67 and a beta of 0.56. Gilead Sciences has a 1 year low of $60.89 and a 1 year high of $85.97. The business has a 50 day simple moving average of $67.74 and a 200-day simple moving average of $73.87. The company has a debt-to-equity ratio of 1.22, a current ratio of 2.33 and a quick ratio of 2.23.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be issued a $0.68 dividend. This represents a $2.72 dividend on an annualized basis and a yield of 4.11%. The ex-dividend date of this dividend is Monday, September 14th. Gilead Sciences’s dividend payout ratio is presently 44.30%.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its holdings in Gilead Sciences by 14.4% in the second quarter. BlackRock Inc. now owns 115,834,270 shares of the biopharmaceutical company’s stock valued at $8,912,289,000 after acquiring an additional 14,619,279 shares during the last quarter. Sontag Advisory LLC lifted its stake in Gilead Sciences by 237.4% during the first quarter. Sontag Advisory LLC now owns 17,971 shares of the biopharmaceutical company’s stock worth $1,344,000 after purchasing an additional 12,644 shares in the last quarter. Quantamental Technologies LLC lifted its stake in Gilead Sciences by 68.4% during the second quarter. Quantamental Technologies LLC now owns 20,323 shares of the biopharmaceutical company’s stock worth $1,564,000 after purchasing an additional 8,255 shares in the last quarter. Busey Wealth Management lifted its stake in Gilead Sciences by 6.4% during the second quarter. Busey Wealth Management now owns 3,388 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 203 shares in the last quarter. Finally, APG Asset Management N.V. lifted its stake in Gilead Sciences by 58.4% during the first quarter. APG Asset Management N.V. now owns 1,133,202 shares of the biopharmaceutical company’s stock worth $84,718,000 after purchasing an additional 417,845 shares in the last quarter. Hedge funds and other institutional investors own 77.87% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

See Also: How to identify percentage decliners

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.